Anil Chandraker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2264952/publications.pdf

Version: 2024-02-01

134 7,921 papers citations

71102 51608 41 h-index

> 9894 citing authors

86

g-index

142 all docs 142 docs citations 142 times ranked

#	Article	IF	Citations
1	Human leukocyte antigen antibody sensitization, lung transplantation, and health equity. American Journal of Transplantation, 2022, 22, 698-704.	4.7	2
2	Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. Journal of the American Society of Nephrology: JASN, 2022, 33, 238-252.	6.1	112
3	Adenosinergic Pathway and Linked Suppression: Two Critical Suppressive Mechanisms of Human Donor Antigen Specific Regulatory T Cell Lines Expanded Post Transplant. Frontiers in Immunology, 2022, 13, 849939.	4.8	2
4	Introduction: Moving Toward a More Personalized Approach to Kidney Transplantation. Seminars in Nephrology, 2022, 42, 1.	1.6	0
5	Follicular T cells mediate donor-specific antibody and rejection after solid organ transplantation. American Journal of Transplantation, 2021, 21, 1893-1901.	4.7	28
6	Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation. Frontiers in Immunology, 2021, 12, 618737.	4.8	12
7	Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection. Journal of the American Society of Nephrology: JASN, 2021, 32, 994-1004.	6.1	44
8	Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection. Journal of Clinical Investigation, 2021, 131 , .	8.2	11
9	Full facial retransplantation in a female patient—Technical, immunologic, and clinical considerations. American Journal of Transplantation, 2021, 21, 3472-3480.	4.7	21
10	Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 2497.	2.4	10
11	The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. Transplantation Reviews, 2021, 35, 100649.	2.9	9
12	Posttransplantation Hypomagnesemia as a Predictor of Better Graft Function after Transplantation. Kidney and Blood Pressure Research, 2020, 45, 982-995.	2.0	3
13	High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury. Journal of Translational Medicine, 2020, $18,175.$	4.4	9
14	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	2.8	37
15	Five-Year Follow-up after Face Transplantation. New England Journal of Medicine, 2019, 380, 2579-2581.	27.0	46
16	Time for reform in transplant program–specific reporting: AST/ASTS transplant metrics taskforce. American Journal of Transplantation, 2019, 19, 1888-1895.	4.7	42
17	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. American Journal of Transplantation, 2019, 19, 2876-2888.	4.7	95
18	Immunologic Risk Assessment and Approach to Immunosuppression Regimen in Kidney Transplantation. Clinics in Laboratory Medicine, 2019, 39, 643-656.	1.4	3

#	Article	IF	CITATIONS
19	First Report of Perfluorobutane Microsphere–Enhanced Ultrasound in the Transplant Kidney. Transplantation, 2019, 103, e283-e284.	1.0	1
20	Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. American Journal of Transplantation, 2019, 19, 1518-1528.	4.7	11
21	Novel Targets of Immunosuppression in Transplantation. Clinics in Laboratory Medicine, 2019, 39, 157-169.	1.4	9
22	Cell Therapy in Solid Organ Transplantation. Current Gene Therapy, 2019, 19, 71-80.	2.0	6
23	Potential Roles of Siglecs in the Regulation of Allo-Immune Reaction. Current Protein and Peptide Science, 2019, 20, 823-828.	1.4	2
24	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	4.7	205
25	Analysis of dendritic cells and ischemia-reperfusion changes in postimplantation renal allograft biopsies may serve as predictors of subsequent rejection episodes. Kidney International, 2018, 93, 1227-1239.	5.2	8
26	IL-6 production by monocytes is associated with graft function decline in patients with borderline changes suspicious for acute T-cell-mediated rejection: a pilot study. Transplant International, 2018, 31, 92-101.	1.6	6
27	Significance of biologics in renal transplantation. Current Opinion in Organ Transplantation, 2018, 23, 51-62.	1.6	5
28	Developing a Rationale for an Appropriate Immunosuppressive Regimen in Lung vs Kidney Transplant Recipients. Transplantation, 2018, 102, S691.	1.0	0
29	The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United States. MDM Policy and Practice, 2018, 3, 238146831878181.	0.9	15
30	New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines. Transplant Infectious Disease, 2018, 20, e12985.	1.7	11
31	Regulatory T Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1760-1764.	4.5	46
32	P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. Journal of Clinical Investigation, 2018, 128, 3490-3503.	8.2	31
33	The promise of organ and tissue preservation to transform medicine. Nature Biotechnology, 2017, 35, 530-542.	17.5	371
34	Integrated Kidney Exosome Analysis for the Detection of Kidney Transplant Rejection. ACS Nano, 2017, 11, 11041-11046.	14.6	106
35	Causes and management of postrenal transplant diarrhea. Current Opinion in Nephrology and Hypertension, 2017, 26, 484-493.	2.0	13
36	The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death. Transplantation, 2017, 101, 2207-2212.	1.0	14

#	Article	IF	Citations
37	Upregulated Heat Shock Proteins After Hyperthermic Chemotherapy Point to Induced Cell Survival Mechanisms in Affected Tumor Cells From Peritoneal Carcinomatosis. Cancer Growth and Metastasis, 2017, 10, 117906441773055.	3.5	25
38	Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients. PLoS ONE, 2017, 12, e0177339.	2.5	12
39	Metabolomic Profiling in Individuals with a Failing Kidney Allograft. PLoS ONE, 2017, 12, e0169077.	2.5	39
40	Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI Insight, 2017, 2, .	5.0	31
41	Longitudinal immunological characterization of the first presensitized recipient of a face transplant. JCI Insight, 2017, 2, .	5.0	18
42	The Limits of Linked Suppression for Regulatory T Cells. Frontiers in Immunology, 2016, 7, 82.	4.8	5
43	Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. International Journal of Molecular Sciences, 2016, 17, 2060.	4.1	45
44	SP690LONG TERM OUTCOMES OF HIGHLY SENSITIZED KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2016, 31, i324-i325.	0.7	0
45	The Real World Impact of APOL1 Variants on Kidney Transplantation. Transplantation, 2016, 100, 16-17.	1.0	9
46	Imaging cell biology in transplantation. Transplant International, 2016, 29, 1349-1351.	1.6	3
47	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2016, 35, 1295-1302.	0.6	12
48	Face Transplantation in a Highly Sensitized Recipient. Military Medicine, 2016, 181, 221-226.	0.8	11
49	Donor-specific antibodies and antibody-mediated rejection in vascularized composite allotransplantation. Current Opinion in Organ Transplantation, 2016, 21, 510-515.	1.6	15
50	Reduction in circulating level of HMGB-1 following continuous renal replacement therapy in sepsis. Cytokine, 2016, 83, 206-209.	3.2	14
51	Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2016, 11, e0158431.	2.5	79
52	Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. Oncotarget, 2016, 7, 68749-68767.	1.8	36
53	TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. International Journal of Oncology, 2015, 47, 857-866.	3.3	69
54	Recombinant <scp>PTH</scp> therapy for severe hypoparathyroidism after kidney transplantation in preâ€transplant parathyroidectomized patients: review of the literature and a case report. Clinical Transplantation, 2015, 29, 951-957.	1.6	10

#	Article	IF	CITATIONS
55	Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival. Journal of the American Society of Nephrology: JASN, 2015, 26, 3102-3113.	6.1	28
56	Salt Accelerates Allograft Rejection through Serum- and Glucocorticoid-Regulated Kinase-1–Dependent Inhibition of Regulatory T Cells. Journal of the American Society of Nephrology: JASN, 2015, 26, 2341-2347.	6.1	43
57	Glomerular Inflammation Correlates With Endothelial Injury and With IL-6 and IL- $\hat{1}^2$ Secretion in the Peripheral Blood. Transplantation, 2014, 97, 1034-1042.	1.0	24
58	Long-Term Outcomes of Kidney Transplantation Across a Positive Complement-Dependent Cytotoxicity Crossmatch. Transplantation, 2014, 97, 1247-1252.	1.0	44
59	Efficacy of Levofloxacin in the Treatment of BK Viremia. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 583-589.	4.5	79
60	VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2013, 32, 120-128.	0.6	53
61	Immunologic monitoring in kidney transplant recipients. Kidney Research and Clinical Practice, 2013, 32, 52-61.	2.2	14
62	Beyond calcineurin inhibitors. Current Opinion in Nephrology and Hypertension, 2013, 22, 689-697.	2.0	14
63	Jagged2â€signaling promotes <scp>IL</scp> â€6â€dependent transplant rejection. European Journal of Immunology, 2013, 43, 1449-1458.	2.9	23
64	A new molecular approach to the diagnosis of acute rejection. Nature Reviews Nephrology, 2013, 9, 631-632.	9.6	0
65	Combination Therapy With Plasmapheresis, IVIG, and Rituximab Provides Benefit in the Management of Early Antibody Mediated Rejection in Lung Transplant in a Pilot Cohort. Chest, 2013, 144, 1018A.	0.8	2
66	Presence of Anti-HLA Antibodies at High Threshold in Patients Listed for Lung Transplantation Is Associated With a Lower Transplant Rate and a Higher Antibody Mediated Rejection Incidence Posttransplant. Chest, 2013, 144, 1015A.	0.8	1
67	The emerging role of the GPR109A (HCA2/PUMAâ€G) receptor in regulating macrophage function. FASEB Journal, 2013, 27, 649.4.	0.5	0
68	Derivation and Validation of a Cytokine-Based Assay to Screen for Acute Rejection in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1018-1025.	4.5	32
69	Stem Cell Therapy in Kidney Transplantation. JAMA - Journal of the American Medical Association, 2012, 308, 130.	7.4	10
70	Deleterious Effect of CTLA4-lg on a Treg-Dependent Transplant Model. American Journal of Transplantation, 2012, 12, 846-855.	4.7	123
71	The APOL1 Genotype of African American Kidney Transplant Recipients Does Not Impact 5-Year Allograft Survival. American Journal of Transplantation, 2012, 12, 1924-1928.	4.7	161
72	Atovaquone versus trimethoprim–sulfamethoxazole as <i><scp>P</scp>neumocystis jirovecii</i> pneumonia prophylaxis following renal transplantation. Clinical Transplantation, 2012, 26, E184-90.	1.6	30

#	Article	IF	CITATIONS
73	Impact of Accidental Discovery of Renal Cell Carcinoma at Time of Renal Transplantation on Patient or Graft Survival. Transplantation, 2011, 92, 1123-1128.	1.0	7
74	Monocyte-Secreted Inflammatory Cytokines Are Associated With Transplant Glomerulopathy in Renal Allograft Recipients. Transplantation, 2011, 91, 552-559.	1.0	30
75	Transitional Cell Carcinoma of the Native Urinary Tract After Kidney Transplantation: Recommendations Following a Long-Term Retrospective Analysis. American Journal of the Medical Sciences, 2011, 341, 478-483.	1.1	17
76	Hypophosphatemia in Kidney Transplant Recipients: Report of Acute Phosphate Nephropathy as a Complication of Therapy. American Journal of Kidney Diseases, 2011, 57, 641-645.	1.9	17
77	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. Journal of Immunology, 2011, 187, 1097-1105.	0.8	159
78	Blockade of Notch Ligand Delta1 Promotes Allograft Survival by Inhibiting Alloreactive Th1 Cells and Cytotoxic T Cell Generation. Journal of Immunology, 2011, 187, 4629-4638.	0.8	38
79	The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo. Journal of Immunology, 2011, 187, 1113-1119.	0.8	115
80	Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney International, 2011, 79, 1005-1012.	5.2	21
81	Evaluation of Fluoroquinolones for the Prevention of BK Viremia after Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1298-1304.	4.5	94
82	Noninfectious Complications after Kidney Transplantation. , 2010, , 568-579.		0
83	Animal Models of Chronic Allograft Injury: Contributions and Limitations to Understanding the Mechanism of Long-Term Graft Dysfunction. Transplantation, 2010, 90, 935-944.	1.0	41
84	Regulatory Allospecific T Cell Clones Abrogate Chronic Allograft Rejection. Journal of the American Society of Nephrology: JASN, 2009, 20, 820-830.	6.1	13
85	Paradoxical Functions of B7: CD28 Costimulation in a MHC Class II-Mismatched Cardiac Transplant Model. American Journal of Transplantation, 2009, 9, 2837-2844.	4.7	27
86	New Approaches For Desensitization Strategies Prior to Kidney Transplantation. American Journal of Kidney Diseases, 2009, 53, 370-372.	1.9	5
87	Predictive biomarkers of renal allograft failure. Expert Opinion on Medical Diagnostics, 2008, 2, 1279-1290.	1.6	2
88	Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy. Circulation, 2008, 117, 660-669.	1.6	89
89	Facial Transplantation and Immunosuppressed Patients: A New Frontier in Reconstructive Surgery. Transplantation, 2008, 85, 1693-1697.	1.0	23
90	Chronic Allograft Nephropathy. Seminars in Nephrology, 2007, 27, 414-429.	1.6	26

#	Article	IF	Citations
91	Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nature Medicine, 2007, 13, 952-961.	30.7	1,862
92	A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. Transplant International, 2007, 20, 505-511.	1.6	16
93	Inhibition of Simian Virus 40 Large T Antigen Helicase Activity by Fluoroquinolones. Antiviral Therapy, 2007, 12, 1-6.	1.0	55
94	BK Viral Reactivation in Cardiac Transplant Patients: Evidence for a Double-hit Hypothesis. Journal of Heart and Lung Transplantation, 2006, 25, 814-819.	0.6	24
95	Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Transplant International, 2006, 19, 351-359.	1.6	31
96	A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrology Dialysis Transplantation, 2006, 21, 3559-3566.	0.7	64
97	Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?. Nature Clinical Practice Nephrology, 2006, 2, 134-135.	2.0	3
98	Induction Therapy: Are We Picking Our Battles?. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 356-357.	4.5	2
99	Mechanisms and Role of HLA and non-HLA Alloantibodies. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 404-414.	4.5	62
100	CTLA-4 Is Important in Maintaining Long-Term Survival of Cardiac Allografts. Transplantation, 2005, 79, 897-903.	1.0	17
101	Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2005, 16, 255-260.	6.1	51
102	Chronic Rejection: Insights from a Novel Immunosuppressive-Free Model of Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2004, 15, 687-694.	6.1	12
103	Pharmacoepidemiology of Anemia in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1347-1352.	6.1	123
104	Interaction Between ICOS-B7RP1 and B7-CD28 Costimulatory Pathways in Alloimmune Responses In Vivo. American Journal of Transplantation, 2003, 3, 390-395.	4.7	32
105	The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo. Journal of Immunology, 2003, 170, 2949-2955.	0.8	86
106	A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients 1. Transplantation, 2003, 76, 798-802.	1.0	223
107	A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection1. Transplantation, 2002, 73, 1736-1742.	1.0	21
108	Mechanisms of targeting cd28 by a signaling monoclonal antibody in acute and chronic allograft rejection1. Transplantation, 2002, 73, 1310-1317.	1.0	34

#	Article	IF	Citations
109	Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney International, 2002, 62, 627-631.	5.2	33
110	CD28-B7-Mediated T Cell Costimulation in Chronic Cardiac Allograft Rejection. American Journal of Pathology, 2001, 158, 977-986.	3.8	63
111	Cutting Edge: Recipient MHC Class II Expression Is Required to Achieve Long-Term Survival of Murine Cardiac Allografts After Costimulatory Blockade. Journal of Immunology, 2001, 167, 5522-5526.	0.8	123
112	Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. Journal of Clinical Investigation, 2001, 107, 909-916.	8.2	89
113	Indirect Allorecognition of Donor Class I and II Major Histocompatibility Complex Peptides Promotes the Development of Transplant Vasculopathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 2500-2506.	6.1	42
114	Hepatocyte Growth Factor Prevents the Development of Chronic Allograft Nephropathy in Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 1280-1292.	6.1	72
115	Human leukocyte antigen matching in renal transplantation: an update. Current Opinion in Nephrology and Hypertension, 2000, 9, 683-687.	2.0	6
116	Bacterial Pathogens Induce Abscess Formation by CD4 + T-Cell Activation via the CD28–B7-2 Costimulatory Pathway. Infection and Immunity, 2000, 68, 6650-6655.	2.2	44
117	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Journal of Clinical Investigation, 2000, 105, 643-651.	8.2	158
118	Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2000, 105, 1109-1116.	8.2	36
119	The Role of B/T Costimulatory Signals in the Immunopotentiating Activity of Neisserial Porin. Journal of Infectious Diseases, 1999, 180, 755-761.	4.0	45
120	Regulatory T Cells Maintain Peripheral Tolerance to Islet Allografts Induced by Intrathymic Injection of MHC Class I Allopeptides. Cell Transplantation, 1999, 8, 375-381.	2.5	15
121	DISTINCT TOLERANCE PATHWAYS IN SENSITIZED ALLOGRAFT RECIPIENTS AFTER SELECTIVE BLOCKADE OF ACTIVATION SIGNAL 1 OR SIGNAL 21. Transplantation, 1999, 68, 288-293.	1.0	24
122	ANTI-CD154 OR CTLA4Ig OBVIATES THE NEED FOR THYMIC IRRADIATION IN A NON-MYELOABLATIVE CONDITIONING REGIMEN FOR THE INDUCTION OF MIXED HEMATOPOIETIC CHIMERISM AND TOLERANCE1. Transplantation, 1999, 68, 1348-1355.	1.0	108
123	Diagnostic techniques in the work-up of renal allograft dysfunction - an update. Current Opinion in Nephrology and Hypertension, 1999, 8, 723-728.	2.0	31
124	In Vitro and in Vivo Immunomodulatory Effects of RDP1258, a Novel Synthetic Peptide. Journal of the American Society of Nephrology: JASN, 1999, 10, 1997-2005.	6.1	26
125	Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance. Journal of Experimental Medicine, 1998, 187, 2037-2044.	8.5	328
126	MECHANISMS OF INDIRECT ALLORECOGNITION. Transplantation, 1998, 65, 876-883.	1.0	44

#	Article	lF	CITATIONS
127	EFFECTS OF EXPLOSIVE BRAIN DEATH ON CYTOKINE ACTIVATION OF PERIPHERAL ORGANS IN THE RAT1. Transplantation, 1998, 65, 1533-1542.	1.0	373
128	COMPARATIVE STUDIES OF SPECIFIC ACQUIRED SYSTEMIC TOLERANCE INDUCED BY INTRATHYMIC INOCULATION OF A SINGLE SYNTHETIC WISTAR-FURTH (RT1u) ALLO-MHC CLASS I (RT1.AU) PEPTIDE OR WAG (RT1u)-DERIVED CLASS I PEPTIDE1. Transplantation, 1998, 66, 1059-1066.	1.0	38
129	THE ROLE OF CTLA4 NEGATIVE SIGNALING PATHWAY IN THE INDUCTION OF ACQUIRED THYMIC TOLERANCE IN VIVO. Transplantation, 1998, 65, S168.	1.0	O
130	CD28-B7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury: Rapid Communication. Kidney International, 1997, 52, 1678-1684.	5.2	98
131	T-CELL COSTIMULATORY BLOCKADE IN EXPERIMENTAL CHRONIC CARDIAC ALLOGRAFT REJECTION. Transplantation, 1997, 63, 1053-1058.	1.0	56
132	INHIBITION OF CD26/DIPEPTIDYL PEPTIDASE IV ACTIVITY IN VIVO PROLONGS CARDIAC ALLOGRAFT SURVIVAL IN RAT RECIPIENTS1,2. Transplantation, 1997, 63, 1495-1500.	1.0	97
133	CD28-B7 T CELL COSTIMULATORY BLOCKADE BY CTLA4lg IN THE RAT RENAL ALLOGRAFT MODEL1,2. Transplantation, 1996, 62, 1942-1945.	1.0	66
134	Transplantation Immunology. , 0, , 649-666.		0